Aplasia pure red cell Trials in Disease

Study on Isatuximab for Treating Pure Red Cell Aplasia in Patients with Major ABO Mismatch After Stem Cell Transplantation

This clinical trial focuses on a specific complication that can occur after allogeneic hematopoietic stem cell transplantation—a condition where the body stops producing red blood cells properly. This happens when there is a major mismatch in blood types between the donor and the recipient, causing the immune system to attack and destroy red blood cell precursors in the bone marrow.

Who can participate:

• Patients aged 15 years or older
• Those who have received an allogeneic stem cell transplant with a major ABO blood type mismatch
• Individuals diagnosed with Pure Red Cell Aplasia, meaning they require regular red blood cell transfusions 60 days after transplant, with a reticulocyte count under 10 G/L
• Patients whose donor cells are working well and whose white blood cells and platelets have recovered
• Those with no return or worsening of their original disease
• Participants must be willing to use effective contraception during treatment and for at least 5 months after the last dose
• Must have health insurance coverage and provide signed informed consent (for those under 18, both parents must sign)

Who cannot participate:

• Patients who have not experienced a major ABO mismatch after stem cell transplant
• Those who have not been diagnosed with Pure Red Cell Aplasia
• Individuals outside the specified age range for the study
• Those unwilling or unable to follow study procedures and requirements
• Patients unable to provide informed consent

What the trial involves:

The study is testing isatuximab, a monoclonal antibody that targets a specific protein called CD38 on the surface of certain cells. This medication helps the immune system identify and destroy these cells, potentially reducing the time it takes for the body to start producing red blood cells again.

Participants are randomly assigned to either receive isatuximab treatment or standard supportive care, which may include blood transfusions. The treatment group receives isatuximab through an intravenous infusion directly into a vein. This randomization typically occurs around six months after the transplant.

Throughout the study, researchers closely monitor several factors including the number of blood transfusions needed, ferritin levels in the blood, and any side effects experienced. Quality of life is evaluated at specific time points: 60 days, 100 days, and several months after transplant. The main goal is to determine how quickly patients can become independent of transfusions and to assess overall health outcomes.

The study is expected to continue until March 20, 2027, and aims to provide valuable insights into whether isatuximab can improve outcomes for patients experiencing this complication after stem cell transplantation.